AC-1204

Cerecin · Phase 2 active Small molecule

At a glance

Generic name	AC-1204
Sponsor	Cerecin
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

AC-1204 26-Week Long Term Efficacy Response Trial With Optional Open-label Ext (PHASE2, PHASE3)
Safety of Caprylic Triglycerides in ALS: A Pilot Study (NA)
Evaluation of PK of Caprylic Triglyceride Oil, AC-1202, AC-1204, and Axona on Ketone Body Production (PHASE1)
Evaluation of PK of AC-1204 Mixed in Water, AC-1202 Mixed in Water, and AC-1202 Mixed in Ensure® on Ketone Body Production (PHASE1)
Evaluation of PK of AC1204 v Caprylic Triglyceride Oil Incl Food Effect on Ketone Body Production (PHASE1)
AC-1204 Long-term Efficacy Response Trial (ALERT Protocol) (PHASE2, PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AC-1204 CI brief — competitive landscape report
AC-1204 updates RSS · CI watch RSS
Cerecin portfolio CI